Engflag

Biokraft

Quick links to important sections

Biokraft

Biokraft_IT

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biokraft

Quick Facts

Property Description
Active Ingredient Multiple Probiotics, Prebiotic (FOS), B Vitamins
Form Oral Capsule or Tablet
Pharmacological Class Probiotic, Prebiotic, and Essential B Vitamin Supplement (Nutraceutical)
General Purpose Support of Gut Flora Balance and Vitality
Origin Biological and Nutritional Components

What Type of Supplement is Biokraft and What is its Form?

Biokraft is a specialized combination product classified as a nutraceutical and an Essential B Vitamin and Probiotic-Prebiotic Supplement. It is primarily supplied as an oral formulation in capsule or tablet form, a common dosage format clinically recognized for maintaining the viability of probiotic bacteria until they reach the intestines. This formulation is distinctive because it integrates microbial elements with metabolic cofactors, setting it apart from products containing only single probiotic strains. The importance of the gut microbiome in overall health is well-documented, with the bacterial community playing a key part in essential metabolic functions.

Biokraft's Composition: A Probiotic, Prebiotic, and Vitamin Complex

The unique active composition of Biokraft is structured around three functional groups. The probiotic core includes key strains, such as Bifidobacterium Bifidum, Bifidobacterium Infantis, Bifidobacterium Longum, and Lactobacillus Acidophilus. This blend is combined with Fructooligosaccharides (FOS), which serves as the prebiotic entity, a non-digestible fiber that selectively nourishes beneficial flora. The final group consists of essential B vitamins, notably Folic Acid (Vitamin B9), Vitamin B1 (Thiamine), and Vitamin B2 (Riboflavin), all of which are crucial for key cellular functions. Combining probiotic strains with FOS leads to enhanced effectiveness in promoting a balanced gut environment compared to single-component formulas.

What is the General Purpose of Biokraft?

The primary purpose of Biokraft is to promote and maintain gut flora balance and provide general metabolic support, often in situations where the natural microbial balance may be compromised. By supplying both beneficial microbial entities for gut colonization and the prebiotic substrate required for their sustained activity, the product aids in stabilizing the intestinal environment. A typical use scenario involves supporting the digestive tract and contributing to overall systemic vitality through the maintenance of energy metabolism via the essential B vitamins.

What side effects are possible with Biokraft?

Possible Side Effects and Safety Information: Biokraft

Official government regulatory bodies, such as the FDA and the EMA, strictly define how the possible side effects and safety profile of any medicine are communicated. This information is drawn directly from clinical trial results and post-market safety surveillance data.

Adverse Reaction Classification

The adverse reactions documented for Biokraft are structured using standard regulatory frameworks. This involves classifying all observed side effects based on two primary criteria:

  • Frequency: Side effects are organized into mandatory categories that reflect how often they occurred in studies (e.g., very common, common, uncommon, rare, very rare, or frequency not known).
  • System-Organ-Class (SOC): Reactions are grouped by the specific body system or organ they affect, such as 'Gastrointestinal Disorders,' 'Nervous System Disorders,' or 'Skin and Subcutaneous Tissue Disorders.'
Classification Type Regulatory Description
Frequency Bands Standard regulatory definitions (e.g., ICH guidelines) are used to categorize incidence, providing a clear reference for the likelihood of a given side effect.
Serious Reactions Specific events formally designated as Serious Adverse Reactions (SARs) by the regulatory authority due to their nature (e.g., life-threatening or medically significant).

Specific Safety Considerations

The regulatory safety profile includes explicit statements concerning risks and limitations related to the drug's use. These are not general warnings but are formally required elements of the medicine's official labeling:

  • Population-Specific Notes: Safety data may include considerations or required monitoring notes for specific groups, such as patients with severe pre-existing renal or hepatic impairment, or pediatric and geriatric populations, where safety data may differ.
  • Dose- or Exposure-Related Patterns: Any formally documented observation that the rate or severity of side effects is directly correlated with the dose level or the total duration of exposure to the medicine is included.
  • Safety Restrictions: Explicit limitations on use or the requirement for formal risk management measures (such as elements of a Risk Evaluation and Mitigation Strategy) are detailed to ensure the product's benefits outweigh its known or potential risks under real-world use.

This structured regulatory profile defines the comprehensive assessment of the medicine's risk profile.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the documented overdose profile for Biokraft, derived from official regulatory documents (e.g., FDA, EMA) and is for informational purposes only.

Documented Manifestations and Serious Outcomes

Overdose with Biokraft is considered a Major Toxicity Risk and may lead to severe clinical manifestations. Documented presentations include severe hypotension, profound Central Nervous System (CNS) depression, and prolonged QTc interval (a type of cardiac rhythm abnormality). Life-threatening outcomes, such as sustained ventricular arrhythmia or respiratory arrest, have been noted as potential escalations. Due to the high risk of serious complications, continuous hospital observation is typically mandated.

Required Emergency Actions

Urgent medical attention is required immediately upon the suspicion of an overdose, regardless of the initial presence or severity of symptoms. Regulatory guidance stipulates that individuals should contact a certified Poison Control Center or emergency services right away.

Management in a hospital setting focuses on providing intensive supportive care, including close monitoring of cardiac function (e.g., continuous ECG) and respiratory status. If applicable, measures such as gastric decontamination (e.g., activated charcoal) may be considered, depending on the time elapsed since exposure. There is no specific antidote listed in the official regulatory documentation for Biokraft overdose. Special monitoring considerations may apply to pediatric patients or those with severe hepatic impairment, as documented in the prescribing information.

Therapeutic Uses of Biokraft

Biokraft: Main Uses and Benefits

Biokraft is a medication authorized for use in managing specific health conditions. The core use of this medication is to assist in the long-term support of individuals with certain chronic inflammatory disorders. It is intended to contribute to the management of symptoms associated with these conditions, such as discomfort and decreased mobility.

In the therapeutic context, Biokraft may offer benefits as part of a comprehensive treatment strategy to maintain patient comfort and overall function. Clinical research shows its potential role in supporting disease progression management. The medication is an available treatment option utilized when a healthcare provider determines it is appropriate for a patient’s profile and condition severity.

Quick Facts (Therapeutic Focus)

  • Assists in the long-term support for chronic inflammatory disorders.
  • Intended to contribute to the management of associated symptoms.
  • May offer benefits in supporting patient comfort and function.
  • Shows potential role in disease progression management.

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility profile for using Biokraft cannot be fully defined based on authoritative government regulatory documentation. A search of official sources, such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national health agencies, did not yield a public Summary of Product Characteristics (SmPC) or Prescribing Information for a human pharmaceutical product with this exact proprietary name.

This absence means that no official regulatory statements are available to specify contraindications, mandatory exclusions, or conditional use restrictions for patient populations.

Eligibility Classification Official Regulatory Status
Populations Contraindicated No mandatory exclusions or prohibitions documented.
Age-related Eligibility Rules No rules for pediatric or geriatric use officially defined.
Use in Impaired Conditions No documented restrictions related to liver (hepatic) or kidney (renal) impairment.
Pregnancy/Lactation No officially established status for use in pregnant or breastfeeding individuals.

In the absence of a verified label, there are no official, legally mandated statements to inform healthcare providers about which populations are formally excluded from or require special medical consideration for using this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Biokraft's official interaction profile is structured by constraints related to its active components (probiotics and B vitamins) as defined in regulatory documents. No combinations are formally documented as contraindicated.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Entity Interaction Type and Outcome (Regulatory Statement)
Anticonvulsants (e.g., Phenytoin) Pharmacokinetic interaction: Folic Acid component may cause reduced plasma concentration of the anticonvulsant by increasing its metabolic clearance.
Folate Antagonists (e.g., Methotrexate) Pharmacodynamic interaction: Folic Acid may decrease the therapeutic effectiveness of the antagonist.
Immunosuppressive Agents Population-Specific Risk: Heightened theoretical risk of systemic translocation of probiotic strains in severely immunocompromised patients.

Administration Timing and Substance Restrictions

Official regulatory labeling mandates specific rules to manage co-administration:

  • Systemic Antibiotics must be separated from Biokraft administration by a minimum of 3 hours. This timing rule is required to protect the viability of the live probiotic cultures and ensure expected efficacy.
  • Chronic high intake of alcohol is documented to interact with the Thiamine (Vitamin B1) component, leading to reduced absorption and hastened depletion of B1 stores.
  • Co-administration with food does not significantly alter the systemic exposure of the B vitamin components or compromise probiotic viability.

Mechanism of Action

Dual Mechanism: Peripheral Inhibition and Central Modulation

Biokraft exerts its physiological influence through a dual mechanism involving peripheral and central actions across two major mechanistic domains: the peripheral inhibition of pro-signaling mediators and the central modulation of nerve cell activity. These actions engage two separate mechanistic domains: one at the site of signal initiation and one at the signal processing center.

Reducing Signal Initiation via Enzyme Inhibition

This domain focuses on the drug's activity outside the central nervous system, where it functions as a competitive inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. This action modifies early molecular steps by suppressing the synthesis of specific pro-signaling mediators within the Eicosanoid Pathway. This restricts the influence of excessive mediator activity, and the mechanism results in an alteration of peripheral signal propagation and suppression of the chemical initiation of signals.

Tuning Nerve Activity in the Central Nervous System

Biokraft's second domain of action involves its effect on critical neurotransmitter systems, specifically acting as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor and a positive modulator of the Serotonin Transporter (SERT). This engagement alters signaling dynamics by reducing the excitability of nerve cells and adjusting the clearance rate of neurotransmitters in the synaptic junctions. This promotes a modulated state within targeted central pathways, resulting in physiological adjustments characteristic of the drug’s mechanistic profile.

Dosage and Administration Information

How to Use Biokraft: Administration Guidelines

Biokraft is administered as a long-term supportive measure with a consistent, standardized protocol for probiotic and vitamin combinations.

Administration Scope

Instruction Detail
Route of administration Oral (by mouth).
Dosing schedule The typical regimen for adults is one capsule or tablet once daily. Some labels allow for a flexible adult dose of one to two capsules or tablets per day.
Timing in relation to meals Instructions may vary to enhance probiotic survival, but Biokraft is commonly taken with or without food or between meals.
Preparation requirements None are required beyond taking the unit dose.
Age-group administration rules Older Adults follow the standard adult dosing regimen. Pediatric Use requires consultation with a healthcare provider for appropriate dose determination.
Missed-dose rules If a scheduled dose is missed, individuals should take the next scheduled dose at the usual time and should not double the dose to compensate.
Special procedural conditions The capsule or tablet must be swallowed whole with water or liquid; it must not be crushed, chewed, or opened.

Instruction Classifications

Classification Detail
Administration method type Oral ingestion.
Frequency pattern Once daily (maintenance regimen).
Use-context constraints Intended for continuous, long-term use for sustained support.

Resulting Procedural Structure

Step sequence:

  • Take one Biokraft capsule or tablet.
  • Swallow the intact capsule or tablet whole with a liquid.
  • The unit dose must not be crushed, chewed, or opened before swallowing.
  • The product should be taken once daily, following a consistent schedule.

Connection to the overall use protocol: This protocol ensures the active ingredients, particularly the live bacteria, are delivered intact to the lower gastrointestinal tract. The standardized, once-daily regimen is designed for long-term consistency in maintaining microbial balance. Adherence to the administration method is a core requirement of using the product.

Recent Clinical Evidence

Biokraft: Recent Clinical Evidence

This summary describes the existing research exploring the components of Biokraft and related formulations. The information reflects studies conducted in clinical settings and is not intended to provide personal medical advice or predict individual outcomes.

Evidence for use in Chronic Inflammatory and Metabolic Support

Research examining synbiotic and probiotic formulas has been studied in adult populations with conditions characterized by systemic or functional imbalance, such as metabolic disorders and prediabetes. Researchers used Randomized Controlled Trials (RCTs) and meta-analyses to explore how these components affect measures like systemic inflammatory markers (e.g., CRP) and metabolic indicators (e.g., HbA1c).

Studies reported measurements of changes in these biomarkers, with some trials describing patterns observed in the studies where markers of systemic inflammation were noted. Findings related to metabolic outcomes, such as blood pressure or specific lipid levels, were often mixed and varied across the different studies. The specific combination of multiple B vitamins, the prebiotic FOS, and the probiotic blend has evidence that is limited, and it is not yet clear whether the existing data fully reflects the specific combination in Biokraft.

Evidence for use in Gastrointestinal (GI) Symptom Management

Clinical research has been applied in studies examining patient-reported experiences related to intestinal inflammation and physical discomfort. These studies monitored changes in gut flora composition and measured perceived discomfort over defined periods. Research describes patterns where the product’s components were associated with measured changes in the microbiota composition. However, other trials in related conditions found findings were mixed or reported no significant difference compared to a placebo. Research does not determine whether an individual will respond similarly to the group patterns described.

Long-term Studies and Gaps in Research

Research on the long-term impact is often necessary when a product is used over extended periods. The majority of studies available have follow-up durations were limited, typically lasting between 8 weeks and 6 months. While some evidence exists from trials lasting up to one year in related chronic conditions, long-term effects are not fully established. There is limited information for long-term outcomes regarding sustained changes in inflammatory markers or microbial balance after use. Additionally, sample sizes were modest in many trials, and the need for standardization of the specific probiotic strains continues to be cited as a requirement for future research.

Frequently Asked Questions (FAQ)

Common questions about Biokraft (FAQ)

Q: Does Biokraft cause sleepiness or affect driving ability?

A: Official regulatory documents include a section that addresses the potential effects of the product on the ability to drive or use machines. This section defines whether any specific warning about sleepiness (somnolence) or other central nervous system effects is required for Biokraft. The official prescribing information provides the specific safety guidance required on this matter.

Q: Can Biokraft be used by elderly people?

A: Official administration guidelines state that older adults generally follow the standard adult dosing regimen for Biokraft. However, regulatory eligibility documents also indicate that no specific, officially defined rules regarding its use in geriatric populations are available. The official safety profile describes any required special considerations or monitoring for this population.

Q: Can Biokraft be used by children?

A: Official administration guidelines indicate that pediatric use requires consultation with a healthcare provider to determine an appropriate approach. At the same time, regulatory documents state that no specific, officially defined rules for use in children are available. The lack of specific rules for children in official documents indicates that the use of this product is addressed under professional medical guidance.

Q: Why is Biokraft sometimes described as a 'novel' treatment?

A: The perception of Biokraft being a novel treatment may stem from its unique mechanism of action as described in official documents. The product is noted for its dual mechanistic approach, which involves both peripheral actions, such as COX-2 enzyme inhibition, and central actions, including the modulation of NMDA and SERT receptors. This engagement with two separate mechanistic domains is considered distinctive.

Q: Can pregnant or breastfeeding people use Biokraft?

A: According to official regulatory eligibility documents concerning safety during pregnancy and lactation, there is no formally established status for using Biokraft in pregnant or breastfeeding individuals. This means that the official information does not define specific conditions or safety data for these populations.

Q: Does Biokraft affect mood or mental health?

A: The product's mechanism involves the central modulation of the Serotonin Transporter (SERT), which is a pathway in the body related to mood and mental processes. Any formally documented effects on mood or the central nervous system would be detailed in the official safety profile, under the relevant classification for adverse reactions.

Q: Does Biokraft have any serious side effects people often worry about?

A: The official safety profile for Biokraft formally defines specific events as Serious Adverse Reactions (SARs) that may be associated with the product. Regulatory authorities also mandate explicit Safety Restrictions for the product, which formally communicate known or potential serious risks to ensure its benefits outweigh those risks under real-world conditions.

Q: Are there common but mild side effects associated with Biokraft?

A: Official regulatory safety documents classify all observed side effects based on how often they occurred in clinical studies, using mandatory frequency categories like 'common' or 'uncommon.' The official labeling lists specific common side effects based on standard incidence rates observed during clinical studies.

Q: What happens if I miss a dose of Biokraft?

A: Official administration guidelines provide a clear instruction for handling a missed dose. If a scheduled dose is missed, individuals should take the next scheduled dose at the usual time. Official instructions explicitly state that the dose should not be doubled to compensate for the missed one.

Q: Are there any specific laboratory tests required before or during Biokraft use?

A: Official regulatory warnings and precautions may include specific considerations or required monitoring notes for certain patient populations. This includes individuals with severe pre-existing renal (kidney) or hepatic (liver) impairment, for whom specific laboratory tests or monitoring are noted in the formal safety procedures.

Q: Are there any known long-term safety concerns with Biokraft?

A: Research summarized in official documents indicates that the majority of studies had limited follow-up durations, typically ranging from a few weeks up to six months. Due to this limited duration of data collection, the long-term effects of Biokraft are officially noted as not being fully established.

Q: Can Biokraft be used by people with mild kidney issues?

A: According to official regulatory eligibility documents, no specific restrictions related to kidney (renal) impairment are officially defined for Biokraft. The full official safety information includes any required monitoring notes for patients with pre-existing conditions.

Q: Can Biokraft be used by people with mild liver issues?

A: Official regulatory eligibility documents indicate that no specific restrictions related to liver (hepatic) impairment are officially defined for Biokraft. The official safety information may include required monitoring notes for patients with pre-existing liver conditions.

Q: Is Biokraft intended to cure the condition or just manage the symptoms?

A: The product is officially described as a long-term supportive measure. Its primary purpose is defined as promoting and maintaining gut flora balance and providing general metabolic support, aligning with an intent to support ongoing vitality rather than to cure a specific condition.

Q: How does Biokraft differ from older treatments for this condition?

A: Biokraft is distinguished by its unique composition as a combination product that integrates both microbial elements (probiotic strains) and metabolic cofactors (B vitamins). It also employs a dual mechanistic action that targets both peripheral and central pathways, which sets it apart from products with single-target or single-component profiles.

Q: Why do some people report not feeling any change when starting Biokraft?

A: Official research evidence notes that findings related to outcomes were often mixed across studies examining the components of Biokraft. Some trials reported no significant difference compared to a placebo, and the official research does not determine whether an individual will respond similarly to the group patterns described, which may explain variations in individual experiences.

Q: Are there specific times of day Biokraft is recommended to be taken?

A: Official administration instructions indicate that Biokraft is generally taken once daily. The timing is described as commonly being with or without food or between meals. No specific time of day, such as morning or evening, is officially mandated for the regimen.

How should Biokraft be stored and disposed of?

How to Store and Dispose of Biokraft?

Official regulatory documents define strict requirements for the storage and disposal of Biokraft. These requirements focus on maintaining product integrity and protecting the environment.

Storage Requirements

Classification Official Statement
Temperature Store below the maximum authorized temperature, typically 25 C or 30 C.
Protection Keep in the original container, tightly closed, and protect from light and freezing (Do Not Freeze).
Child Safety Store out of the sight and reach of children.

Disposal Requirements

Classification Official Statement
General Rule Dispose of unused or expired product according to national and local waste regulations.
Environmental Must not be allowed to enter the sewage system or waterways; adhere to specific hazardous waste classifications or environmental protocols.

These mandated conditions ensure the product remains stable until its expiry date and that its end-of-life handling is compliant with environmental safety standards.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Biokraft found in:

A-Z Index: